Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta (Nasdaq:NKTX) reported first quarter 2026 results and NKX019 clinical progress. Cash, cash equivalents and investments were $266.7 million on March 31, 2026, with funding expected to support operations into 2029.
Enrollment continues in Ntrust-1 and Ntrust-2 at a 4 billion cell NKX019 dose, with protocol changes enabling outpatient dosing and rheumatoid arthritis patients. Initial clinical data are planned for presentation at a medical meeting in 2026. First quarter net loss was $27.8 million, or $0.37 per share.
Nkarta (Nasdaq: NKTX) reached agreement with the FDA to amend Ntrust-1 and Ntrust-2 protocols to permit outpatient dosing of NKX019, reducing post-dose monitoring from 24 hours to 2 hours.
The amendments also allow an option to re-dose, add a rheumatoid arthritis cohort to Ntrust-2, continue dosing at a 4 billion cell level (12 billion cells per three-dose cycle), and remove geographic monitoring requirements; initial data are expected at a medical meeting this year.
Nkarta (Nasdaq: NKTX) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel at 11:45 a.m. ET on “Cell Therapy in Autoimmune.” President Nadir Mahmood will deliver a fireside chat at 3:45 p.m. ET covering updates on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the company’s Investors website, with a replay archived for approximately 90 days.
Nkarta (Nasdaq: NKTX) reported fourth-quarter and full-year 2025 results and clinical progress on March 25, 2026. The company had $295.1 million of cash and investments as of December 31, 2025, which it says will fund operations into 2029. Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 (12 billion cells per cycle). Initial clinical data from Ntrust-1 and Ntrust-2 are targeted for presentation at a medical conference in 2026. Full-year R&D was $90.4 million and net loss was $104.1 million (or $1.41 per share).
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 and the Leerink Global Healthcare Conference on March 10, 2026.
Each appearance is a fireside chat (9:10 a.m. EST on March 2; 10:40 a.m. EDT on March 10). A simultaneous webcast will be available on the company Investors site, with a replay archived for approximately 90 days.
Nkarta (Nasdaq: NKTX) will participate in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025. Management will appear in a 10:50 a.m. ET fireside chat. A simultaneous webcast will be available on Nkarta’s Investors website, with a replay archived for approximately 90 days.
The presentation focuses on Nkarta’s clinical-stage engineered natural killer (NK) cell therapies for autoimmune diseases and provides an investor access point via live webcast and short-term replay.
Nkarta (NASDAQ:NKTX) reported third-quarter 2025 results and clinical progress for its NKX019 autoimmune program on Nov 10, 2025. Key points: $316.5 million cash and investments at Sept 30, 2025, expected to fund operations into 2029; enrollment began in the second dose-escalation cohort after a combined iDSMB cleared simultaneous dosing across Ntrust-1 and Ntrust-2; modified lymphodepletion with fludarabine plus cyclophosphamide produced complete B-cell depletion in treated patients versus partial depletion with cyclophosphamide alone. Initial NKX019 data are planned for a medical conference in 2026.
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:40 a.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 13, 2025 at 5:00 p.m. ET. A simultaneous webcast will be available on the company’s Investors website at www.nkartatx.com, and a replay will be archived on the site for approximately 90 days.
Nkarta (Nasdaq: NKTX) will present a poster at ACR Convergence 2025 in Chicago on Sunday, October 26, 2025, reporting clinical and preclinical data for its investigational therapy NKX019.
Data to be presented show robust CD19+ B‑cell depletion with subsequent B‑cell reconstitution consistent with immune reset in participants with non‑Hodgkin lymphoma, plus preclinical results showing depletion of pathogenic B cells in in vivo lymphoma models and in vitro autoimmune models and trafficking to lymphoid organs.
Poster details: Presenting author Mira Tohmé; time 10:30 AM–12:30 PM CT; room Hall F1; poster number 0014. Nkarta will also exhibit at booth #1801.
Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company will engage in a fireside chat on September 9, 2025, at 8:30 a.m. ET.
Investors can access a live webcast of the presentation through Nkarta's website, with a replay available for approximately 90 days following the event.